Status:
COMPLETED
Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Obstructive Pulmonary Disease (COPD)
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.
Eligibility Criteria
Inclusion
- Males and females aged ≥ 40 years with a clinical diagnosis of moderate to severe stable COPD
Exclusion
- History or current diagnosis of asthma, recent respiratory tract infection or acute COPD exacerbation, life expectancy of less than 1 year, known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
804 Patients enrolled
Trial Details
Trial ID
NCT00358436
Start Date
August 1 2006
End Date
June 1 2008
Last Update
January 4 2017
Active Locations (120)
Enter a location and click search to find clinical trials sorted by distance.
1
Almirall Investigational Sites#926
Jasper, Alabama, United States, 35501
2
Almirall Investigational Sites#858
Ozark, Alabama, United States, 36360
3
Almirall Investigational Sites#900
Phoenix, Arizona, United States, 85023
4
Almirall Investigational Sites#899
Tucson, Arizona, United States, 85715